Panelists discuss how SGLT2 inhibitors evolved from diabetes medications to become foundational heart failure therapy with class I recommendations across the ejection fraction spectrum, providing ...

In patients with type 1 diabetes (T1D), sodium-glucose cotransporter 2 (SGLT2) inhibitors plus glucagon receptor antagonists (GRAs) may improve glycemic control, reduce insulin use, and mitigate ...

Study findings indicate synergistic effects of SGLT2 inhibitors and MRAs on albuminuria. Combining a sodium-glucose cotransporter-2 (SGLT2) inhibitor and mineralocorticoid receptor antagonist (MRA) ...

Please provide your email address to receive an email when new articles are posted on . Patients with heart failure who received an SGLT2 inhibitor were less likely to experience sudden cardiac death ...

BOSTON -- Sodium-glucose cotransporter-2 (SGLT2) inhibitors were linked to long-term reductions in mortality risk among patients with pulmonary arterial hypertension (PAH), according to an ...

Results to be Presented at the European Society for Cardiology Congress Demonstrate Differential Effects During Endothelial Dysfunction in Cell Studies A manuscript entitled “Metabolic, Intestinal, ...

Author: Deepak L. Bhatt, MD, MPH, MBA, Director of Mount Sinai Fuster Heart Hospital and the Dr. Valentin Fuster Professor of Cardiovascular Medicine at the Icahn School of Medicine at Mount Sinai ...

Most patients who qualified for an SGLT2 inhibitor were not prescribed one, according to an analysis of more than 3 million U.S. adults. SGLT2 inhibitor prescription rates were low among patients with ...

Adding an SGLT2 inhibitor to standard care did not improve clinical outcomes in critically ill patients with acute organ dysfunction, an open-label randomized trial involving intensive care units ...

The SGLT2 inhibitor empagliflozin (Jardiance) nabbed a new indication for the treatment of adults with chronic kidney disease (CKD) regardless of diabetes status, Boehringer Ingelheim and Eli Lilly ...